Inventor · disambiguated record
Madhusudan Natarajan
Also filed as: NATARAJAN MADHUSUDAN
7 granted patents·15 pending applications·9 citations·filing 2013–2025
78Inventor score
Top patents by PatentIndex Score
22 records- 0194US11498953B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2021·Granted Nov 15, 2022·6 cites·21 claims
- 0291US11434276B2Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of useINVETX INC·Filed 2021·Granted Sep 6, 2022·2 cites·13 claims
- 0390US11739135B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Aug 29, 2023·1 cites·9 claims
- 0485US2024166749A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0585US2024239896A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0685US2024166748A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0785US2024239897A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0881US2023279118A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 0980US2025304650A1Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2025·Application pending·0 cites
- 1079US12344650B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Jul 1, 2025·0 cites·18 claims
- 1177US2024327497A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 1271US11542333B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 3, 2023·0 cites·9 claims
- 1371US2023127241A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 1470US11548949B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 10, 2023·0 cites·7 claims
- 1563US2024034779A1Antibodies targeting complement factor d and uses therofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1657US2024175054A1Composition and methods for the treatment of fabry diseaseTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 1754US11059906B2Anti-CCL2 and anti-LOXL2 combination therapy for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Jul 13, 2021·0 cites·4 claims
- 1851US2015158942A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 1950US2018179275A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 2045US2016289319A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Application pending·0 cites
- 2143US2023038502A1Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikreinSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 2238US2019085095A1Anti-c5 antibodies with enhanced ph switchSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →